The role of GLP‐1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
In people with type 2 diabetes mellitus (T2DM), the incretin effect is reduced, but the recent advent of dipeptidyl peptidase‐4 inhibitors and glucagon‐like peptide (GLP)‐1 agonists/analogues has enabled restoration of at least some of the function of the incretin system, with accompanying improvements in glycaemic control. Two GLP‐1 receptor agonists/analogues are currently approved for the treatment of T2DM—exenatide (Byetta®, Eli Lilly & Co., Indianapolis, IN, US) and liraglutide (Victoza®, Novo Nordisk, Bagsvaerd, Denmark); a once‐weekly formulation of exenatide (Bydureon®, Eli Lilly & Co.) has also been approved by the European Medicines Agency. The National Institute for Health and Clinical Excellence (NICE) has recently published guidance on the use of liraglutide in T2DM, based on evidence from the Liraglutide Effect and Action in Diabetes (LEAD) Phase III trial programme, which compared liraglutide with existing glucose‐lowering therapies, such as exenatide and insulin glargine. The LEAD programme reported HbA1c reductions from 0.8 to 1.5% with liraglutide (1.2 and 1.8 mg), accompanied by low rates of hypoglycaemia and some weight loss; side effects were primarily gastrointestinal in nature (e.g. nausea and diarrhoea). Based on the findings of the LEAD studies and the NICE recommendation, liraglutide now represents an important therapy widely available in the UK for certain patient groups, including those with a body mass index (BMI) ≥35.0 kg/m 2 , and patients with a BMI <35 kg/m 2 who are considered unsuitable for insulin and are failing to meet targets for glycaemic control with oral agents. NICE guidelines still suggest that most patients without considerable obesity (BMI <35 kg/m 2 ) are probably best managed using insulin therapy. Evidence also suggests a future role for GLP‐1 mimetics in combination with basal insulin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“8 mg/day or exenatide 10 μg twice daily over 26 weeks of treatment [30].”
BackgroundRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“When exogenous GLP-1 is administered to patients, blood-glucose regulation via endogenous insulin secretion is restored [10].”
BackgroundGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · cited 1×
“8 mg (Table 1), with more patients achieving glycaemic targets compared with those receiving glimepiride (with or without metformin) in the LEAD-2 and -3 studies [26,27].”
BackgroundNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 1×
“Incretin hormones potentiate glucose-induced insulin secretion and are responsible for around 70% of postprandial insulin secretion in healthy individuals, as well as inhibiting glucagon secretion from the pancreatic alpha-cells in the presence of hyperglycaemia, thereby reducing hepatic glucose output [6,8].”
BackgroundZinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Cited by
Diabetes, oxidative stress and therapeutic strategies
Rochette, L., Zeller, M., Cottin, Y., & Vergely, C. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.05.017 · Cited by 530
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217
“The glucose-dependent action of liraglutide on insulin secretion is in line with the low risk of hypoglycaemia observed in clinical trials with liraglutide [15].”
BackgroundResultGLP-1 mimetics and diabetic ketoacidosis: possible interactions and clinical consequences
Forouzanmehr, B., Hemmati, M. A., Atkin, S. L., Jamialahmadi, T., Yaribeygi, H., & Sahebkar, A. (2025) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-024-03384-1 · Cited by 3
“There are four main types of diabetes including type 1 (T1DM), which is caused by insufficient insulin production from the pancreas; type 2 (T2DM), which is caused by insulin resistance in adipocytes and skeletal muscle cells and a gradual decline in insulin production; gestational diabetes, which develops during preg…”
InfluentialSbraccia, P., Aberle, J., Olsen, A. H., Rathor, N., & Major‐Pedersen, A. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14945 · Cited by 3
“Liraglutide is a human glucagon-like peptide-1 receptor agonist (GLP-1RA) that has been shown to improve glycaemic control in patients with type 2 diabetes (T2D) by increasing insulin production and suppressing glucagon secretion in a glucose-dependent manner.(1-5) In addition to improved glycaemic control, many patie…”
Background
Metadata
- Authors
- Barnett, A. H.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-12-22
- Volume
- 14
- Issue
- 4
- Pages
- 304-314
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1978191819
- Cited by
- 54
- References
- 18
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of GLP‐1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01523.x
- The paper
- Barnett, A. H. (2012). The role of GLP‐1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01523.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.